Resistance Profiles and Virulence Factors of Enteric Escherichia coli in Chronic Kidney Disease Patients at Laquintinie Hospital in Douala, Cameroon.

IF 3.2 Q3 MICROBIOLOGY
International Journal of Microbiology Pub Date : 2025-09-12 eCollection Date: 2025-01-01 DOI:10.1155/ijm/5624252
Ballue Serges T Dadjo, Armelle T Mbaveng, Jean W Marbou Takougoum, Ornella D Tsobeng, Michael F Kengne, Victor Kuete
{"title":"Resistance Profiles and Virulence Factors of Enteric <i>Escherichia coli</i> in Chronic Kidney Disease Patients at Laquintinie Hospital in Douala, Cameroon.","authors":"Ballue Serges T Dadjo, Armelle T Mbaveng, Jean W Marbou Takougoum, Ornella D Tsobeng, Michael F Kengne, Victor Kuete","doi":"10.1155/ijm/5624252","DOIUrl":null,"url":null,"abstract":"<p><p><i>Escherichia coli</i> is commonly found in human feces and is the most prevalent resistant microorganism in patients with chronic kidney disease. Several studies demonstrated that virulence factors were a major cause of the emergence of pathogenic strains of <i>E. coli</i>. This study's objective was to determine the antibiotic resistance profile, detect virulence factors, and assess the prevalence of carriage of extended-spectrum beta-lactamase (ESBL) genes in fecal <i>E. coli</i> isolates obtained from chronic kidney disease patients. This research was carried out in Laquintinie Hospital of Douala between January 2022 and December 2023. In total, 458 patients with (<i>n</i> = 197) or without (<i>n</i> = 261) chronic kidney disease and suffering from gastroenteritis constituted the total population. <i>E. coli</i> isolates were obtained by using eosin methylene blue (EMB) agar and identified by the API 20E gallery system. The Kirby-Bauer method was used to determine the isolates' antibiotic resistance profile. The simplex polymerase chain reaction (PCR) served to detect virulence factors and resistance genes. It appeared that all antibiotics tested, except nalidixic acid, presented a significant resistance (<i>p</i> < 0.05) in chronic kidney disease patients contrasted to patients without chronic kidney disease. The antibiotic susceptibility testing revealed a high level of resistance to amoxicillin (94.5%), amoxicillin-clavulanic acid (79.5%), trimethoprim/sulfamethoxazole (69.9%), and ofloxacin (65.8%) in patients with chronic kidney disease. <i>E. coli</i> isolates showed (<i>p</i> < 0.001) a significantly high rate of multidrug resistance phenotype in chronic kidney disease patients (74.0%) as compared to patients without chronic kidney disease (35.7%). According to the virulence genes detected, the most prevalent pathotype of <i>E. coli</i> was the enteropathogenic <i>E. coli</i> (40.8%; <i>n</i> = 40), followed by enterotoxigenic <i>E. coli</i> (29.6%; <i>n</i> = 29) and shiga toxin-producing <i>E. coli</i> (29.6%; <i>n</i> = 29). The screening of resistance genes in pathotypes of <i>E. coli</i> has demonstrated that <i>bla</i> <sub>TEM</sub> (76.5%; <i>n</i> = 75) and <i>bla</i> <sub>CTX-M</sub> (75.5%; <i>n</i> = 74) were the more frequent ESBL resistance genes encountered. This study showed that a high rate of resistance, multidrug resistance, and a high frequency of enteropathogenic <i>E. coli</i> and ESBL resistance genes in <i>E. coli</i> were most often found in chronic kidney disease patients. This high level of enteric multidrug-resistant <i>E. coli</i> in chronic kidney disease patients exposes them to hazardous antibiotic treatment and serious public health issues.</p>","PeriodicalId":14098,"journal":{"name":"International Journal of Microbiology","volume":"2025 ","pages":"5624252"},"PeriodicalIF":3.2000,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12449115/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Microbiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/ijm/5624252","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Escherichia coli is commonly found in human feces and is the most prevalent resistant microorganism in patients with chronic kidney disease. Several studies demonstrated that virulence factors were a major cause of the emergence of pathogenic strains of E. coli. This study's objective was to determine the antibiotic resistance profile, detect virulence factors, and assess the prevalence of carriage of extended-spectrum beta-lactamase (ESBL) genes in fecal E. coli isolates obtained from chronic kidney disease patients. This research was carried out in Laquintinie Hospital of Douala between January 2022 and December 2023. In total, 458 patients with (n = 197) or without (n = 261) chronic kidney disease and suffering from gastroenteritis constituted the total population. E. coli isolates were obtained by using eosin methylene blue (EMB) agar and identified by the API 20E gallery system. The Kirby-Bauer method was used to determine the isolates' antibiotic resistance profile. The simplex polymerase chain reaction (PCR) served to detect virulence factors and resistance genes. It appeared that all antibiotics tested, except nalidixic acid, presented a significant resistance (p < 0.05) in chronic kidney disease patients contrasted to patients without chronic kidney disease. The antibiotic susceptibility testing revealed a high level of resistance to amoxicillin (94.5%), amoxicillin-clavulanic acid (79.5%), trimethoprim/sulfamethoxazole (69.9%), and ofloxacin (65.8%) in patients with chronic kidney disease. E. coli isolates showed (p < 0.001) a significantly high rate of multidrug resistance phenotype in chronic kidney disease patients (74.0%) as compared to patients without chronic kidney disease (35.7%). According to the virulence genes detected, the most prevalent pathotype of E. coli was the enteropathogenic E. coli (40.8%; n = 40), followed by enterotoxigenic E. coli (29.6%; n = 29) and shiga toxin-producing E. coli (29.6%; n = 29). The screening of resistance genes in pathotypes of E. coli has demonstrated that bla TEM (76.5%; n = 75) and bla CTX-M (75.5%; n = 74) were the more frequent ESBL resistance genes encountered. This study showed that a high rate of resistance, multidrug resistance, and a high frequency of enteropathogenic E. coli and ESBL resistance genes in E. coli were most often found in chronic kidney disease patients. This high level of enteric multidrug-resistant E. coli in chronic kidney disease patients exposes them to hazardous antibiotic treatment and serious public health issues.

Abstract Image

Abstract Image

Abstract Image

喀麦隆杜阿拉laquininie医院慢性肾病患者肠道大肠杆菌的耐药概况和毒力因素
大肠杆菌常见于人类粪便,是慢性肾脏疾病患者中最常见的耐药微生物。几项研究表明,毒力因素是大肠杆菌致病性菌株出现的主要原因。本研究的目的是确定抗生素耐药谱,检测毒力因素,并评估从慢性肾病患者获得的粪便大肠杆菌分离株中携带广谱β -内酰胺酶(ESBL)基因的流行程度。这项研究于2022年1月至2023年12月在杜阿拉的Laquintinie医院进行。共有458名患有(n = 197)或未患有(n = 261)慢性肾脏疾病并患有胃肠炎的患者构成了总人群。采用伊红亚甲基蓝(EMB)琼脂法分离得到大肠杆菌,采用API 20E gallery系统进行鉴定。采用Kirby-Bauer法测定菌株的耐药谱。单纯聚合酶链反应(PCR)用于检测毒力因子和抗性基因。与非慢性肾病患者相比,慢性肾病患者除萘啶酸外,其他所有抗生素的耐药性均显著(p < 0.05)。药敏试验显示,慢性肾病患者对阿莫西林(94.5%)、阿莫西林-克拉维酸(79.5%)、甲氧苄啶/磺胺甲恶唑(69.9%)和氧氟沙星(65.8%)的耐药水平较高。大肠杆菌分离株显示,慢性肾病患者(74.0%)的多药耐药表型率显著高于非慢性肾病患者(35.7%)(p < 0.001)。从检测到的毒力基因来看,大肠杆菌病原菌最多的是肠致病性大肠杆菌(40.8%,n = 40),其次是肠产毒素大肠杆菌(29.6%,n = 29)和产志贺毒素大肠杆菌(29.6%,n = 29)。大肠杆菌病原菌耐药基因筛选结果显示,bla TEM (76.5%, n = 75)和bla CTX-M (75.5%, n = 74)是ESBL耐药基因中较为常见的。本研究显示,高耐药率、多药耐药率、高频率的肠致病性大肠杆菌和大肠杆菌中ESBL耐药基因在慢性肾病患者中最为常见。慢性肾病患者肠道中这种高水平的耐多药大肠杆菌使他们面临危险的抗生素治疗和严重的公共卫生问题。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
7.90
自引率
0.00%
发文量
57
审稿时长
13 weeks
期刊介绍: International Journal of Microbiology is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies on microorganisms and their interaction with hosts and the environment. The journal covers all microbes, including bacteria, fungi, viruses, archaea, and protozoa. Basic science will be considered, as well as medical and applied research.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信